Abstract
The interactions of synthetic and natural anthracyclines were studied by determination of binding constants to calf thymus DNA using spectrophotometric titration and thermal denaturation of drug-DNA solutions to determine the Tm values. The two ways of evaluation of DNA-drug interaction showed reasonable correlation. In particular, the glycosides with non-natural aglycones or major structural deviation showed consistently lower binding constants and Tm values. In the case of daunorubicin and 4-demethoxydaunorubicin these data also correlated reasonably with antitumor efficacy. However, in other instances, there were many deviations and a direct simple correlation between binding parameters and biological activity can not be established.
Keywords: DNA-drug binding constants, Anthraquinone, Daunosamine glycosides, DNA, Intercalation, Thermal denaturation, Melting points Tm
Current Bioactive Compounds
Title: Interaction of Natural and Synthetic Anthracyclines with DNA (Supporting Material)
Volume: 4 Issue: 3
Author(s): Karsten Krohn
Affiliation:
Keywords: DNA-drug binding constants, Anthraquinone, Daunosamine glycosides, DNA, Intercalation, Thermal denaturation, Melting points Tm
Abstract: The interactions of synthetic and natural anthracyclines were studied by determination of binding constants to calf thymus DNA using spectrophotometric titration and thermal denaturation of drug-DNA solutions to determine the Tm values. The two ways of evaluation of DNA-drug interaction showed reasonable correlation. In particular, the glycosides with non-natural aglycones or major structural deviation showed consistently lower binding constants and Tm values. In the case of daunorubicin and 4-demethoxydaunorubicin these data also correlated reasonably with antitumor efficacy. However, in other instances, there were many deviations and a direct simple correlation between binding parameters and biological activity can not be established.
Export Options
About this article
Cite this article as:
Krohn Karsten, Interaction of Natural and Synthetic Anthracyclines with DNA (Supporting Material), Current Bioactive Compounds 2008; 4 (3) . https://dx.doi.org/10.2174/157340708786305943
DOI https://dx.doi.org/10.2174/157340708786305943 |
Print ISSN 1573-4072 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6646 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Role of Secondary Alcohol Metabolites in Anthracycline Cardiotoxicity: from Hypotheses to New Drugs
Drug Design Reviews - Online (Discontinued) Immunotherapy for Prostate Cancer
Current Pharmaceutical Design Combretastatin A-4 Analogs as Anticancer Agents
Mini-Reviews in Medicinal Chemistry Imaging Features of Primary Tumors of the Hand
Current Medical Imaging Small Molecule Tyrosine Kinase Inhibitors: Potential Role in Pediatric Malignant Solid Tumors
Current Cancer Drug Targets Interactions of Phenothiazines with Lipid Bilayer and their Role in Multidrug Resistance Reversal
Current Drug Targets Natural Products Inhibiting the Ubiquitin-Proteasome Proteolytic Pathway, A Target for Drug Development
Current Medicinal Chemistry How Much of the Proteome Do We See with Discovery-Based Proteomics Methods and How Much Do We Need to See?
Current Proteomics siRNA Modifications and Sub-Cellular Localization: A Question of Intracellular Transport?
Current Pharmaceutical Design Doxorubicin Sensitizes the Non-Small Cell Lung Cancer Cells to Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Mediated (TRAIL) Apoptosis In Vitro but not In Vivo
Letters in Drug Design & Discovery Novel Systemic Drugs for Cutaneous T-Cell Lymphoma
Recent Patents on Anti-Cancer Drug Discovery Mechanisms and Inhibitors of Apoptosis in Cardiovascular Diseases
Current Pharmaceutical Design The Chick Embryo Chorioallantoic Membrane as a Model for in vivo Research on Anti-Angiogenesis
Current Pharmaceutical Biotechnology Evaluation of Fluorescence Resonance Energy Transfer Approaches as a Tool to Quantify the Stability of Antisense Oligodeoxynucleotides
Current Pharmaceutical Analysis Kirsten Rat Sarcoma Viral Oncogene Homologue (KRAS) Mutations in the Occurrence and Treatment of Pancreatic Cancer
Current Topics in Medicinal Chemistry Telomerase Inhibition in Cancer Therapeutics: Molecular-Based Approaches
Current Medicinal Chemistry Interferon-Beta Therapy Monitoring in Multiple Sclerosis Patients
Endocrine, Metabolic & Immune Disorders - Drug Targets Peptidic Tumor Targeting Agents: The Road from Phage Display Peptide Selections to Clinical Applications
Current Pharmaceutical Design Protein Interaction Domains: Structural Features and Drug Discovery Applications (Part 2)
Current Medicinal Chemistry Process Variables and Design of Experiments in Liposome and Nanoliposome Research
Mini-Reviews in Medicinal Chemistry